Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.
2.

Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.

Ibbotson T, McGavin JK, Goa KL.

Am J Cardiovasc Drugs. 2003;3(5):381-6. Review.

PMID:
14728074
4.

An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.

Adgey AA.

Eur Heart J. 1998 Apr;19 Suppl D:D10-21. Review.

PMID:
9597518
5.

An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.

Adgey AA.

Am Heart J. 1998 Apr;135(4):S43-55. Review.

PMID:
9539495
6.

[Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].

Auer J, Berent R, Lassnig E, Weber T, Maurer E, Eber B.

Herz. 2003 Aug;28(5):393-403. Review. German.

PMID:
12928738
7.

Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.

Lincoff AM, Califf RM, Topol EJ.

J Am Coll Cardiol. 2000 Apr;35(5):1103-15. Review.

8.
9.

A risk-benefit assessment of abciximab in angioplasty.

Kleiman NS.

Drug Saf. 1999 Jan;20(1):43-57. Review.

PMID:
9935276
11.
12.
13.
14.

Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention.

Cheng JW.

Am J Health Syst Pharm. 2002 Nov 1;59(21 Suppl 7):S5-14. Review.

PMID:
12434710
15.

New antiplatelet agents: platelet GPIIb/IIIa antagonists.

Coller BS, Anderson K, Weisman HF.

Thromb Haemost. 1995 Jul;74(1):302-8. Review.

PMID:
8578476
16.

Role of abciximab in the treatment of coronary artery disease.

Gabriel HM, Oliveira EI.

Expert Opin Biol Ther. 2006 Sep;6(9):935-42. Review.

PMID:
16918260
17.
18.
19.
20.

Acute profound thrombocytopenia following abciximab therapy.

Bishara AI, Hagmeyer KO.

Ann Pharmacother. 2000 Jul-Aug;34(7-8):924-30. Review.

PMID:
10928405

Supplemental Content

Support Center